This trial was meant to be a phase 1/2, with UTI patients treated in H2 2023.
Instead, as seems to be the trend with Recce, the trial took way longer and ended up only completing the phase 1.
Have a look at the AGM presentation from November. Even then they were claiming to aim to start a phase 3 UTI trial in 2024!
Many of us knew it was ridiculous at the time. I don't know how management thought that giving such a timeline was appropriate.
CR presentation doesn't include sepsis as a target indication anymore, surprise surprise. Yet the company has yet to actually front up honestly about the terrible plasma pharmacokinetics.
They said some of the funds are for new pre-clinical programs. I wonder if they're trying to find a formulation with a longer plasma half-life.
Anyway, bring on the loooooong overdue phase 2 UTI trial!
- Forums
- ASX - By Stock
- RCE
- Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete, page-49
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
|
|||||
Last
49.5¢ |
Change
0.010(2.06%) |
Mkt cap ! $114.6M |
Open | High | Low | Value | Volume |
48.5¢ | 51.0¢ | 48.5¢ | $1.909K | 3.908K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 15775 | 48.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 66869 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 15775 | 0.485 |
1 | 25000 | 0.480 |
3 | 249999 | 0.475 |
3 | 10641 | 0.470 |
1 | 12500 | 0.465 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 66666 | 1 |
0.510 | 45304 | 3 |
0.515 | 1504 | 1 |
0.550 | 29407 | 2 |
0.570 | 44444 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online